- Home
- NMRK vs RARE Comparison
NMRK vs RARE Comparison
Compare NMRK & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- RARE
- Stock Information
- Founded
- NMRK 1929
- RARE 2010
- Country
- NMRK United States
- RARE United States
- Employees
- NMRK N/A
- RARE N/A
- Industry
- NMRK Real Estate
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- RARE Health Care
- Exchange
- NMRK Nasdaq
- RARE Nasdaq
- Market Cap
- NMRK 3.4B
- RARE 3.0B
- IPO Year
- NMRK 2017
- RARE 2014
- Fundamental
- Price
- NMRK $17.92
- RARE $31.69
- Analyst Decision
- NMRK Strong Buy
- RARE Strong Buy
- Analyst Count
- NMRK 5
- RARE 14
- Target Price
- NMRK $19.00
- RARE $86.64
- AVG Volume (30 Days)
- NMRK 1.3M
- RARE 1.7M
- Earning Date
- NMRK 10-30-2025
- RARE 11-04-2025
- Dividend Yield
- NMRK 0.67%
- RARE N/A
- EPS Growth
- NMRK 44.43
- RARE N/A
- EPS
- NMRK 0.36
- RARE N/A
- Revenue
- NMRK $2,983,234,000.00
- RARE $610,159,000.00
- Revenue This Year
- NMRK $17.66
- RARE $19.72
- Revenue Next Year
- NMRK $9.19
- RARE $23.29
- P/E Ratio
- NMRK $49.80
- RARE N/A
- Revenue Growth
- NMRK 17.28
- RARE 26.77
- 52 Week Low
- NMRK $9.65
- RARE $25.81
- 52 Week High
- NMRK $19.78
- RARE $58.00
- Technical
- Relative Strength Index (RSI)
- NMRK 51.06
- RARE 57.87
- Support Level
- NMRK $16.91
- RARE $30.95
- Resistance Level
- NMRK $17.64
- RARE $32.30
- Average True Range (ATR)
- NMRK 0.46
- RARE 1.18
- MACD
- NMRK -0.20
- RARE 0.25
- Stochastic Oscillator
- NMRK 47.20
- RARE 86.59
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.